- Azitra broadened enrollment criteria for topical ATR-04 Phase 1/2 trial to include rashes from KRAS and MEK inhibitors.
- Expansion follows Safety Review Committee recommendation to advance to Cohort 2 (~24 patients).
- Modifications aim to expand addressable market and accelerate trial enrollment.
?? Positive AI Sentiment (+3.0 / 10)